LUXTURNA and other potential one-time therapies face unique health insurance challenges given current practices and regulations in the U.S. We have been working with stakeholders across the healthcare sector to help ensure that appropriate patients have access to a product that challenges all of the current conventions of how patients are treated, how products are delivered and how payments are handled.” “We believe that access to therapy is a shared responsibility among Spark Therapeutics, payers, health benefit providers, physicians and treatment centers. Marrazzo, chief executive officer of Spark Therapeutics. “To help ensure eligible patients have access to LUXTURNA, we are striving to bring the same level of innovation applied in development to the delivery of, and access to, this product,” said Jeffrey D. LUXTURNA should only be administered to patients who have viable retinal cells as determined by their treating physicians. Spark Therapeutics has reached agreement in principle with Harvard Pilgrim to make LUXTURNA available under the outcomes-based rebate arrangement and the innovative contracting model that aims to reduce risk and financial burden for payers and treatment centers. Spark Therapeutics also has reached an agreement in principle with affiliates of Express Scripts to enable the innovative contracting model. patients have access to LUXTURNA, a one-time gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Together, these initiatives aim to help ensure eligible U.S. 03, 2018 (GLOBE NEWSWIRE) - Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced three new payer programs: an outcomes-based rebate arrangement with a long-term durability measure, an innovative contracting model and a proposal to CMS under which payments for LUXTURNA™ (voretigene neparvovec-rzyl) would be made over time. Proposal to the Centers for Medicare and Medicaid Services(CMS) would enable Spark Therapeutics to offer payers the option to spread payment over multiple years Harvard Pilgrim and affiliates of Express Scripts have agreed in principle to participate discussions underway with additional commercial insurers while aiming to reduce risk and financial burden for payers and treatment centers

Company offers outcomes-based rebates and an innovative contracting model that support patient access in the U.S.

Spark therapeutics